MIDATECH PHARMA PLC-ADR (MTP) Stock Price, Forecast & Analysis
USA - NASDAQ:MTP - US59564R5000 - ADR
MTP Key Statistics, Chart & Performance
The current stock price of MTP is 0.2851 USD. In the past month the price decreased by -47.19%. In the past year, price decreased by -93.38%.
MTP Latest News, Press Relases and Analysis
MTP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About MTP
Company Profile
Midatech Pharma Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 20 full-time employees. The company went IPO on 2014-12-08. The firm is focused on improving the bio-delivery and biodistribution of medicines. The firm's technologies include Q-Sphera, MidaSolve and MidaCore. Q-Sphera technology focusses on long acting injectables using three-dimensional (3D) printing technology. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. The company has a pipeline of approximately 10 earlier stage programmes, which includes MTD211 (Schizophrenia, MDD), MTD219 (Prophylaxis, transplant rejection), MTX223, MTX213, MTX214, MTX110 (Glioblastoma), MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma) and MTX114 (Psoriasis).
Company Info
MIDATECH PHARMA PLC-ADR
Oddfellows Hse, 19 Newport Road
Abingdon OXFORDSHIRE CF24 0AA GB
CEO: Stephen Stamp
Employees: 20
Phone: 4401235888300.0
MIDATECH PHARMA PLC-ADR / MTP FAQ
What does MTP do?
Midatech Pharma Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 20 full-time employees. The company went IPO on 2014-12-08. The firm is focused on improving the bio-delivery and biodistribution of medicines. The firm's technologies include Q-Sphera, MidaSolve and MidaCore. Q-Sphera technology focusses on long acting injectables using three-dimensional (3D) printing technology. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. The company has a pipeline of approximately 10 earlier stage programmes, which includes MTD211 (Schizophrenia, MDD), MTD219 (Prophylaxis, transplant rejection), MTX223, MTX213, MTX214, MTX110 (Glioblastoma), MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma) and MTX114 (Psoriasis).
What is the stock price of MIDATECH PHARMA PLC-ADR today?
The current stock price of MTP is 0.2851 USD. The price decreased by -18.52% in the last trading session.
Does MIDATECH PHARMA PLC-ADR pay dividends?
MTP does not pay a dividend.
What is the ChartMill technical and fundamental rating of MTP stock?
MTP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does MIDATECH PHARMA PLC-ADR belong to?
MIDATECH PHARMA PLC-ADR (MTP) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of MIDATECH PHARMA PLC-ADR (MTP) based on its PE ratio?
MIDATECH PHARMA PLC-ADR (MTP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.96).
Who owns MIDATECH PHARMA PLC-ADR?
You can find the ownership structure of MIDATECH PHARMA PLC-ADR (MTP) on the Ownership tab.
MTP Technical Analysis
MTP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MTP. Both the profitability and financial health of MTP have multiple concerns.
MTP Financial Highlights
Over the last trailing twelve months MTP reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS increased by 58.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.07 |